As part of the investment, the company opened a biomass power plant in Ingelheim, Germany, in January this year, and completed the Biologicals Development Centre in Biberach last year. A chemical ...

Onsite at the Boehringer Ingelheim R&D centre in Biberach, Germany, the conversation also circled around Boehringer’s One Medicine Platform, originally announced in March 2022, but the central ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

Boehringer Ingelheim is supporting this transformation by partnering with groups working across psychiatric R&D, from small molecules to digital therapeutics. Recognizing the potential to improve ...